Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-03-02
2010-11-30
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07842714
ABSTRACT:
The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
REFERENCES:
patent: 3278447 (1966-10-01), McNicholas
patent: 3890319 (1975-06-01), Danielewicz
patent: 4382892 (1983-05-01), Hayakawa
patent: 4407792 (1983-10-01), Schoenwald
patent: 4454151 (1984-06-01), Waterbury
patent: 4474787 (1984-10-01), Cairns
patent: 4861514 (1989-08-01), Hutchings
patent: 5017229 (1991-05-01), Burns
patent: 5021416 (1991-06-01), Gluchowski
patent: 5089509 (1992-02-01), Chandraradna
patent: 5106615 (1992-04-01), Dikstein
patent: 5110493 (1992-05-01), Cherng-Chyi et al.
patent: 5212162 (1993-05-01), Missel
patent: 5414011 (1995-05-01), Fu et al.
patent: 5459133 (1995-10-01), Neufeld
patent: 5460834 (1995-10-01), Bhagat
patent: 5527893 (1996-06-01), Burns
patent: 5648074 (1997-07-01), Park
patent: 5688819 (1997-11-01), Woodward
patent: 5703077 (1997-12-01), Burke
patent: 5773440 (1998-06-01), Burke
patent: 5811446 (1998-09-01), Thomas
patent: 5858346 (1999-01-01), Vehige
patent: 5888493 (1999-03-01), Sawaya
patent: 5922773 (1999-07-01), Lipton
patent: 6056950 (2000-05-01), Saettone
patent: 6255299 (2001-07-01), Deleuran
patent: 7045121 (2006-05-01), Chang
patent: 7491383 (2009-02-01), Woodward
patent: 2002/0103255 (2002-08-01), Hellberg
patent: 2002/0198209 (2002-12-01), Woodward
patent: 2002/0198210 (2002-12-01), Woodward
patent: 2003/0069286 (2003-04-01), Chen
patent: 2007/0287741 (2007-12-01), Herzberg et al.
patent: 2008/0039398 (2008-02-01), Ousler, III et al.
patent: 2009/0010850 (2009-01-01), Ousler, III et al.
patent: 0524587 (1993-01-01), None
patent: 0590786 (1993-06-01), None
patent: 0705878 (1996-04-01), None
patent: 2007091 (1979-05-01), None
patent: WO 92-02515 (1992-02-01), None
patent: WO 92-20349 (1992-11-01), None
patent: WO 93-17664 (1993-09-01), None
patent: WO 00-54762 (2000-09-01), None
patent: WO 01-01959 (2001-01-01), None
patent: WO 02-05853 (2002-01-01), None
patent: WO 03-051332 (2003-06-01), None
patent: WO2005/101982 (2005-11-01), None
patent: WO2006/071601 (2006-07-01), None
Ahuja, M et al. The AAPS Journal. 2008. vol. 10(2): 229-241.
Allergan “Refresh Lubricant Eyedrops” retrieved on Apr. 3, 2003 from: www.drugstore.com/qxp72838—333181—sespider/allergan/refresh—liquigel—lubricant—eye—drops.htm.
AQUALON® CMC, Physical and Chemical Properties, Hercules incorporated, printed from http://www.herc.com/aqualon/product—data/brochures/250—10.pdf on Jul. 3, 2008, 1999, 30 pages.
Fodor et al., Mechanism of Tetracaine Block of Cyclic Nucleotide-gated Channels, 1997, J. Gen. Physiol., Abstract printed from hyyp://www.jpg.org/cgi/content/abstract/109/1/3 on Jul. 4, 2008, vol. 109, No. 1, 3-14—Abstract only.
LaMotte et al.: The Effect of Artificial Tears With Different CMC Formulations on Contrast Sensitivity. ARVO Annual Meeting Abstract Search and Program Planner, vol. 2002, 2002 pg. Abstract No. 3151.
MayoClinic.com, Dry Eyes, Printed from http://www.mayoclinic.com/health/dry-eyes/DS00463/METHOD=print&DSECTION=all on Jul. 1, 2010, 14 pages.
MedlinePlus, U.s. National Library of Medicine and National Institutes of Health, Dry Eye Syndrome, Printed from http://www.nlm.nih.gov/medlineplus/ency/article/000426.htm on Jul. 1, 2010, 2 pages.
Simmons P.A.: Refresh Liquigel ™: A New Approach to the Treatment of Persistent Dry Eye, Practical Optometry 2002 Canada, vol. 13, No. 2, 2002, pp. 68-71.
UIC Department of Ophthalmology and Visual Sciences, Dry Eyes, Printed from http://www.uic.edu/com/eye/learningaboutvision/eyefacts/dryeyes.shtml on Jul. 1, 2010, 6 pages.
www.rxlist.com, Alcaine-Clinical Pharmacology, http://www.rxlist.com/cgi/generic/propara—cp.htm, printed Jul. 4, 2008, 2 pages.
Guidera, Ann C.; et al.: Keratitis, Ulceration, and Perforation Associated with Topical Nonsteroidal Anti-Inflammatory Drugs. The American Adcademy of Ophthalmology, 2001, 108 (5), pp. 936-944.
Jaanus, Siret D.; et al.: Anti-infalmmatory Drugs. Clinical Ocular Pharmacology, Bartlet, J.D. and Jaanus, S.D., Ed., Boston: Heineman, 2001, pp. 265-298.
Solomon, Kerry D.; et al.: Comparison of Ketorolac Tromethamine 0.5% and Rimexolone 1% to Control Inflammation After Cataract Extraction. J. Cataract Refract Surg., 2001, 27(8) pp. 1231-1237.
Teal, Patricia; et al.: Corneal Subepithelial Infiltrates Following Excimer Laser Photorefractive Keratectomy. J Cataract Refract Surg., 1995, 21(5) pp. 516-518.
Waterbury, et al.,Efficacy of Low Concentrations of Ketorolac Tromethamine in Animal Models of Ocular Inflammation, 2004, vol. 20, No. 4, pp. 345-352.
Waterbury, et al.,Comparison of Ketorolac Tromethamine, Dlclofenac Sodium, and Loteprednol Etabonate in an Animal Model of Ocular Inflammation, 2006, vol. 32, No. 3, pp. 155-159.
Price F, Tonen E, VanDenburgh A. Cheetham JK, Schiffman R. Safety and efficacy of reformulated ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. Association for Research and Vision in Ophthalmology 2003: Poster 2611. Presented May 6, 2003 at 8:30:00 AM.
Sandoval et al.; “Evaluation of 0.4% Ketorolac Tromethamine Ophthalmic Solution Versus 0.5% Ketorolac Tromethamine Ophthalmic Solution After Phacoemulsification and Intraocular Lens Implantation” Journal of Ocular Pharmacology And Therapeutics vol. 22, No. 4, 2006; pp. 251-257.
Whittpenn “Acular LS: Reduced Discomfort without Loss of Efficiency” Ophthalmology Management, May 2005.
Attar Mayssa
Chang Chin-Ming
Farnes Eldon Q.
Graham Richard S.
Schiffman Rhett M.
Allergan Inc.
Blakely, III Nelson C
Ene Doina G.
Forrestal Kevin J.
Spivack Phyllis G.
LandOfFree
Ketorolac tromethamine compositions for treating ocular pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ketorolac tromethamine compositions for treating ocular pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ketorolac tromethamine compositions for treating ocular pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208178